Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Histamine and the response to IFN-alpha in chronic hepatitis C.
Hellstrand K, Brune M, Mellqvist UH, Norkrans G, Lundberg PA, Hermodsson S, Wejstål R. Hellstrand K, et al. J Interferon Cytokine Res. 1998 Jan;18(1):21-2. doi: 10.1089/jir.1998.18.21. J Interferon Cytokine Res. 1998. PMID: 9475663
Histamine in cancer immunotherapy.
Hellstrand K, Hermodsson S, Brune M, Naredi P, Carneskog J, Mellqvist UH. Hellstrand K, et al. Scand J Clin Lab Invest. 1997 May;57(3):193-202. doi: 10.3109/00365519709060027. Scand J Clin Lab Invest. 1997. PMID: 9238754 Review.
Histamine and cytokine therapy.
Hellstrand K, Hermodsson S, Naredi P, Mellqvist UH, Brune M. Hellstrand K, et al. Acta Oncol. 1998;37(4):347-53. doi: 10.1080/028418698430566. Acta Oncol. 1998. PMID: 9743456 Review.
Histamine: a novel approach to cancer immunotherapy.
Hellstrand K, Brune M, Naredi P, Mellqvist UH, Hansson M, Gehlsen KR, Hermodsson S. Hellstrand K, et al. Cancer Invest. 2000;18(4):347-55. doi: 10.3109/07357900009012178. Cancer Invest. 2000. PMID: 10808371 Review.
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Nasic S, Westin J, Hellstrand K, Norkrans G, Lagging M. Alsiö Å, et al. Among authors: hellstrand k. PLoS One. 2012;7(5):e37521. doi: 10.1371/journal.pone.0037521. Epub 2012 May 24. PLoS One. 2012. PMID: 22655053 Free PMC article. Clinical Trial.
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud PY, Negro F, Pawlotsky JM, Zeuzem S, Ferrari C, Norkrans G, Wejstål R, Westin J, Neumann AU, Haagmans BL, Lindh M, Missale G, Hellstrand K, Lagging M. Söderholm J, et al. Among authors: hellstrand k. PLoS One. 2013;8(2):e56991. doi: 10.1371/journal.pone.0056991. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437290 Free PMC article.
203 results